Rosenberg’s Molecular and Genetic Basis of Neurologic and Psychiatric Disease, Sixth Edition: Volume One, provides a comprehensive introduction and reference to the foundations and key practical aspects relevant to neurologic and psychiatric disease. A favorite of over three generations of students, clinicians and scholars, this new edition retains and expands the informative, concise and critical tone of the first edition. This is an essential reference for general medical practitioners, neurologists, psychiatrists, geneticists, and related professionals, and for the neuroscience and neurology research community. The content covers all aspects essential to the practice of neurogenetics to inform clinical diagnosis, treatment and genetic counseling. Every chapter has been thoroughly revised or newly commissioned to reflect the latest scientific and medical advances by an international team of leading scientists and clinicians. The contents have been expanded to include disorders for which a genetic basis has been recently identified, together with abundant original illustrations that convey and clarify the key points of the text in an attractive, didactic format. Comprehensive coverage of the neurogenetic foundation of neurological and psychiatric disease Provides a detailed introduction on both the clinical and basic research implications of molecular and genetics surrounding the brain Includes new chapters on molecular genomics, CRISPR and the most recent updates in molecular genetics

European Cooperation in Science and Technology (COST) supports the collaboration of nationally-funded science and technology research through the creation of networks. COST is the longest-running European framework enhancing cooperation among researchers, engineers and scholars across Europe. The COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” is a good example of the advances possible through interdisciplinary collaboration on difficult problems. COST Action CM1103 brought together 28 research groups from 18 countries to collaborate for four years on multi-target drug design for complex neuropathologies. The interdisciplinary expertise of the members is spans the range from computational enzymology to human studies, providing outstanding opportunities for the interdisciplinary development of trainees, and is reflected in the articles in this e-book. This Research Topic covers progress in multi-target drug design for the complex neuropathologies of the monoamine system that are apparent, for example, in Alzheimer’s disease. After a mini-review to introduce the topic of multi-target drug design, the other articles review the Research topic from their own perspective, two from computational approaches, three from medicinal chemistry, two from molecular pharmacology, and two from studies in whole brain. This multi-faceted approach describes new compounds, new methodology, and advances in the basic science of understanding the brain. This Ebook is based upon work from COST Action (CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain"), supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a pan-European intergovernmental framework. Its mission is to enable break-through scientific and technological developments leading to new concepts and products and thereby contribute to strengthening Europe’s research and innovation capacities. It allows researchers, engineers and scholars to jointly develop their own ideas and take new initiatives across all fields of science and technology, while promoting multi- and interdisciplinary approaches. COST aims at fostering a better integration of less research intensive countries to the knowledge hubs of the European Research Area. The COST Association, an International not-for-profit Association under Belgian Law, integrates all management, governing and administrative functions necessary for the operation of the framework. The COST Association has currently 36 Member Countries. www.cost.eu

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. Volume 10 of the series continues to present novel information about new and interesting approaches to treat common neurological disorders, with a focus on neurodegeneration and pain medicine. The volume presents 7 detailed reviews in total. - Neurodegenerative disease: prevention and treatment through plant extracts therapy - Emerging novel approaches and recent advances in Parkinson’s disease treatment and diagnosis - Neurotrophic factors to combat neurodegeneration - Neural bases of executive function in ADHD children as assessed using FNIRS - Modulation of mesenchymal stem cells, glial cells and the immune system by oligodeoxynucleotides as a novel multi-target therapeutic approach against chronic pain - Chronic pain: focus on anticonvulsants - A review of the impact of testosterone on brain and aging-related decline in brain behavioural function

This book systemically describes the mechanisms underlying the neural regulation of metabolism. Metabolic diseases, including obesity and its associated conditions, currently affect more than 500 million people worldwide. Recent research has shown that the neural regulation of metabolism is a central mechanism that controls metabolic status physiologically and pathophysiologically. The book first introduces the latest studies on the neural and cellular mechanisms of hypothalamic neurons, hypothalamic glial cells, neural circuitries, cellular signaling pathways, and synaptic plasticity in the control of appetite, body weight, feeding-related behaviors and metabolic disorders. It then summarizes the humoral mechanisms by which critical adipocyte-derived hormones and lipoprotein lipase regulate lipid and glucose metabolism, and examines the role of the hypothalamus-sympathetic nerve, a critical nerve pathway from CNS to peripheral nervous system (PNS), in the regulation of metabolism in multiple tissues/organs. Furthermore, the book discusses the functions of adipose tissue in energy metabolism. Lastly, it explores dietary interventions to treat neural diseases and some of the emerging technologies used to study the neural regulation of metabolism. Presenting cutting-edge developments in the neural regulation of metabolism, the book is a valuable reference resource for graduate students and researchers in the field of neuroscience and metabolism.

The U.S. investment in Alzheimer¿s research through the Nat. Inst. of Health (NIH) has resulted in accelerating progress on several research fronts and laid the groundwork for future discovery. This report highlights key findings related to: discovery of new genes and biological mechanisms that cause Alzheimer¿s disease; earlier disease detection using neuro-imaging and biomarkers; links between Alzheimer¿s and other age-related diseases; rapid translation of lab findings to potential treatments; lifestyle factors that may protect against the disease; successful cognitive aging; clinical trials underway now to prevent or treat Alzheimer¿s and cognitive decline; research-tested strategies to support caregivers. Illus. This is a print on demand report.

"Frontiers in CNS Drug Discovery" is an Ebook series devoted to publishing the latest and the most important advances in Central Nervous System (CNS) drug design and discovery. Eminent scientists write contributions on all areas of rational drug design an